Beijing Scitech-mq Pharmaceuticals Limited

Other

Chenming Hu

Qiang Zhang

Yansheng Liu

Xingfu Li

Hongbo Zhang

Leifu Yang

Hailong Yang

Shannan Yu

Nanqiao Zheng

Shouye Feng

Likai Zhou

Zhanqiang Xu

Zhongxiang Wang

Shaohua Zhang

Yueming Sun

Lantao Li

Provided are an acylamino bridged heterocyclic compound of formula (I) or a pharmaceutically acceptable salt, an isomer, a solvate, a crystal, or a prodrug thereof, and a pharmaceutical composition comprising the compound, and an application of the compound or composition in drug preparation. The compound and the pharmaceutically acceptable salt, the isomer, the solvate, the crystal, or the prodrug thereof and the like can be used for treatment or prevention of autoimmune diseases, tumors, and neurodegenerative diseases related to receptor-interacting protein kinase-1 (RIPK1).

Acylamino bridged heterocyclic compound, and composition and application thereof

The present invention relates to an urea-substituted aromatic ring-linked dioxinoquinoline compound of formula (I), or a pharmaceutically acceptable salt or a hydrate thereof. The invention also provides a preparation method of the compound of formula (I) and a pharmaceutically acceptable salt thereof, as well as uses thereof as a drug, wherein the drug acting as a tyrosine kinase (i.e. VEGFR-2, C-RAF, B-RAF, and RET) inhibitor is used for treating disorders related to tyrosine kinase. 

Urea-substituted aromatic ring-linked dioxinoquinoline compounds, preparation method and uses thereof

The present invention relates to a dioxinoquinoline compound of formula (I) or a pharmaceutically acceptable salt thereof. The invention also provides a preparation method of the compound of formula (I) and a pharmaceutically acceptable salt thereof, as well as uses thereof as a drug, wherein the drug acting as a tyrosine kinase (i.e. VEGFR-2 and c-MET) inhibitor is used for treating disorders related to tyrosine kinase. 

Dioxinoquinoline compounds, preparation method and uses thereof

The present disclosure relates to a novel compound as a JAK inhibitor, a composition, and an application thereof. Specifically, the present disclosure provides a compound having high JAK inhibitory activity (as represented by formula (I)) or its isomer, solvate, hydrate, pharmaceutically-acceptable salt, and prodrug, and a pharmaceutical composition containing the compound. Also disclosed is a use of the present compound or pharmaceutical composition in preparation of a medicament for treating autoimmune diseases or cancers. 

2-substituted pyrazole amino-4-substituted amino-5-pyrimidine formamide compound, composition, and application thereof

Growing community of inventors

Beijing, China

Chenming Hu